UBU5:F:F-UBS (Irl) ETF Public Limited Company - MSCI USA Value UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 98.4

Change

+1.94 (+2.01)%

Market Cap

USD 0.56B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-08 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

+16.90 (+3.22%)

USD 101.74B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.52 (+1.02%)

USD 101.37B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 96.03B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.15 (+0.97%)

USD 57.02B
XJSE:F Xtrackers II - Japan Governmen..

-0.07 (-0.91%)

USD 53.72B
VUSA:F Vanguard Funds Public Limited ..

+2.49 (+2.65%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+3.25 (+1.42%)

USD 45.80B
0ZC:F Zscaler Inc

+1.20 (+0.59%)

USD 37.92B
BSND:F Danone SA

N/A

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

+0.84 (+0.68%)

USD 24.77B

ETFs Containing UBU5:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.00% 24% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.00% 24% F 41% F
Trailing 12 Months  
Capital Gain 0.94% 37% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.94% 35% F 47% F
Trailing 5 Years  
Capital Gain 59.07% 60% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.07% 60% D- 46% F
Average Annual (5 Year Horizon)  
Capital Gain 12.22% 78% C+ 70% C-
Dividend Return 12.22% 76% C+ 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.90% 51% F 85% B
Risk Adjusted Return 94.77% 88% B+ 91% A-
Market Capitalization 0.56B 63% D 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike